3x5 Special Opportunity Fund

3x5 Special Opportunity Fund, L.P. is an investment firm that focuses on later-stage companies, particularly in the healthcare and clean-tech sectors. The fund aims to identify and support businesses that are poised for growth and innovation within these industries. By concentrating on established companies, 3x5 seeks to leverage opportunities that arise from advancements in healthcare technologies and sustainable energy solutions, contributing to both economic growth and societal benefits.

Anthony Arnerich

Managing Director, General Partner and Chairman

14 past transactions

Fervo Energy

Series B in 2021
Fervo Energy, founded in 2017 and based in San Francisco, California, specializes in the development and commercialization of next-generation geothermal power technology. The company focuses on owning, developing, and operating geothermal assets to generate clean, carbon-free energy in new locations. By leveraging innovations in geoscience, Fervo Energy aims to accelerate the transition to a sustainable energy future, positioning itself as a key player in the evolution of the electric grid. Its proprietary technology serves as a dispatchable foundation for achieving a fully clean energy system, enabling clients to enhance productivity and scalability in energy production.

Arch Oncology

Series B in 2019
Arch Oncology, Inc. is an immuno-oncology company focused on discovering and developing antibody therapeutics for the treatment of solid tumors and hematologic cancers. Established in 2006 and headquartered in Brisbane, California, with a research laboratory in St. Louis, Missouri, the company specializes in anti-CD47 antibodies that represent a novel class of checkpoint inhibitors. These second-generation antibodies are designed to engage both the adaptive and innate immune systems, effectively targeting and killing tumor cells. By harnessing the body's immune response, Arch Oncology aims to provide new treatment options for patients battling cancer.

Amplyx Pharmaceuticals

Series C in 2017
Amplyx Pharmaceuticals is a small molecule drug development company focused on creating innovative therapies for life-threatening infections, particularly in patients with compromised immune systems. Founded in 2006 and based in San Diego, California, the company specializes in developing oral and injectable anti-infective drugs, including antifungal agents aimed at treating invasive fungal infections caused by pathogens such as Candida and Aspergillus. Amplyx employs a unique platform approach that enhances the efficacy and reduces the toxicity of existing drugs by combining them with additional small molecules. This strategy addresses critical treatment needs in hospital settings and provides effective therapy options for patients after discharge, particularly those undergoing chemotherapy and other immunosuppressive treatments.

Securus Medical Group

Series C in 2016
Securus Medical Group engages in the development of clinical tools to improve the safety and efficacy of ablation therapy by providing real-time, non-contact, high-resolution tissue temperature monitoring, and mapping products. The company engages in developing real-time, noncontact, thermal mapping systems to determine intrabody tissue temperatures.

Amplyx Pharmaceuticals

Series B in 2016
Amplyx Pharmaceuticals is a small molecule drug development company focused on creating innovative therapies for life-threatening infections, particularly in patients with compromised immune systems. Founded in 2006 and based in San Diego, California, the company specializes in developing oral and injectable anti-infective drugs, including antifungal agents aimed at treating invasive fungal infections caused by pathogens such as Candida and Aspergillus. Amplyx employs a unique platform approach that enhances the efficacy and reduces the toxicity of existing drugs by combining them with additional small molecules. This strategy addresses critical treatment needs in hospital settings and provides effective therapy options for patients after discharge, particularly those undergoing chemotherapy and other immunosuppressive treatments.

Tryton Medical

Venture Round in 2014
Tryton Medical, Inc. is a medical device company based in Durham, North Carolina, specializing in the development and manufacturing of side branch stent systems designed to treat coronary bifurcation lesions in patients with cardiovascular diseases. Founded in 2003, the company provides its innovative Tryton Side Branch Stent System, which targets atherosclerotic lesions at bifurcation sites. Tryton Medical distributes its products through a global network of distributors and also addresses investigational needs within the United States. The company's offerings are available in several countries, including Austria, Belgium, Denmark, Ireland, Luxembourg, the Netherlands, Norway, Poland, Portugal, Spain, and the United Kingdom.

Vapotherm

Series B in 2014
Vapotherm, Inc. is a medical technology company specializing in the development and commercialization of proprietary Hi-VNI technology products designed to treat patients of all ages experiencing respiratory distress. Headquartered in Exeter, New Hampshire, the company offers a range of precision flow systems, including Precision Flow Hi-VNI, Precision Flow Plus, Precision Flow Classic, and Precision Flow Heliox, which deliver heated, humidified, and oxygenated air at high velocity through a small-bore nasal interface. Vapotherm also provides various companion products, such as the Vapotherm Transfer Unit for patient mobility, the Q50 compressor for compressed air, and aerosol solutions for medication delivery. Additionally, the company offers disposable products, including single-use nasal interfaces and Oxygen Assist Modules to help clinicians maintain target oxygen levels. Vapotherm generates revenue primarily through direct sales to hospitals in the United States and through distributors in select international markets. Founded in 1993, the company is committed to enhancing clinical outcomes and improving the quality of life for patients.

ZS Pharma

Series D in 2014
ZS Pharma, Inc. is a biopharmaceutical company based in Coppell, Texas, focused on developing non-absorbed drugs for renal, cardiovascular, liver, and metabolic diseases. Established in 2008, the company specializes in highly selective ion-trap therapies, particularly its lead candidate, ZS-9. This innovative treatment employs proprietary zirconium silicate technology to create ion traps that can effectively reduce excess potassium levels in patients suffering from hyperkalemia, a serious condition often associated with chronic kidney disease, hypertension, diabetes, and heart failure. ZS-9 is currently undergoing late-stage clinical trials to evaluate its efficacy and safety. As of December 2015, ZS Pharma operates as a subsidiary of Zeneca, Inc.

Vendscreen

Venture Round in 2014
VendScreen specializes in enhancing the vending experience through its innovative touch screen devices, which can be integrated into new machines or retrofitted onto existing ones. The company offers a user-friendly interface that allows consumers to access nutrition information and advertisements at the point of purchase, facilitating informed decisions while complying with calorie disclosure regulations. VendScreen's technology wirelessly connects to a cloud-based server, ensuring real-time updates of product and inventory data without requiring user input. The system supports various payment methods, including cashless options, and provides operators with valuable analytics and reporting tools. By enabling a seamless interaction between consumers, operators, and advertisers, VendScreen aims to transform traditional vending into a more engaging and informative experience.

Securus Medical Group

Series B in 2013
Securus Medical Group engages in the development of clinical tools to improve the safety and efficacy of ablation therapy by providing real-time, non-contact, high-resolution tissue temperature monitoring, and mapping products. The company engages in developing real-time, noncontact, thermal mapping systems to determine intrabody tissue temperatures.

Vapotherm

Series A in 2013
Vapotherm, Inc. is a medical technology company specializing in the development and commercialization of proprietary Hi-VNI technology products designed to treat patients of all ages experiencing respiratory distress. Headquartered in Exeter, New Hampshire, the company offers a range of precision flow systems, including Precision Flow Hi-VNI, Precision Flow Plus, Precision Flow Classic, and Precision Flow Heliox, which deliver heated, humidified, and oxygenated air at high velocity through a small-bore nasal interface. Vapotherm also provides various companion products, such as the Vapotherm Transfer Unit for patient mobility, the Q50 compressor for compressed air, and aerosol solutions for medication delivery. Additionally, the company offers disposable products, including single-use nasal interfaces and Oxygen Assist Modules to help clinicians maintain target oxygen levels. Vapotherm generates revenue primarily through direct sales to hospitals in the United States and through distributors in select international markets. Founded in 1993, the company is committed to enhancing clinical outcomes and improving the quality of life for patients.

Tryton Medical

Venture Round in 2013
Tryton Medical, Inc. is a medical device company based in Durham, North Carolina, specializing in the development and manufacturing of side branch stent systems designed to treat coronary bifurcation lesions in patients with cardiovascular diseases. Founded in 2003, the company provides its innovative Tryton Side Branch Stent System, which targets atherosclerotic lesions at bifurcation sites. Tryton Medical distributes its products through a global network of distributors and also addresses investigational needs within the United States. The company's offerings are available in several countries, including Austria, Belgium, Denmark, Ireland, Luxembourg, the Netherlands, Norway, Poland, Portugal, Spain, and the United Kingdom.

Vendscreen

Series B in 2012
VendScreen specializes in enhancing the vending experience through its innovative touch screen devices, which can be integrated into new machines or retrofitted onto existing ones. The company offers a user-friendly interface that allows consumers to access nutrition information and advertisements at the point of purchase, facilitating informed decisions while complying with calorie disclosure regulations. VendScreen's technology wirelessly connects to a cloud-based server, ensuring real-time updates of product and inventory data without requiring user input. The system supports various payment methods, including cashless options, and provides operators with valuable analytics and reporting tools. By enabling a seamless interaction between consumers, operators, and advertisers, VendScreen aims to transform traditional vending into a more engaging and informative experience.

ZS Pharma

Series C in 2012
ZS Pharma, Inc. is a biopharmaceutical company based in Coppell, Texas, focused on developing non-absorbed drugs for renal, cardiovascular, liver, and metabolic diseases. Established in 2008, the company specializes in highly selective ion-trap therapies, particularly its lead candidate, ZS-9. This innovative treatment employs proprietary zirconium silicate technology to create ion traps that can effectively reduce excess potassium levels in patients suffering from hyperkalemia, a serious condition often associated with chronic kidney disease, hypertension, diabetes, and heart failure. ZS-9 is currently undergoing late-stage clinical trials to evaluate its efficacy and safety. As of December 2015, ZS Pharma operates as a subsidiary of Zeneca, Inc.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.